Jamison Wright 4/28/25 Jamison Wright 4/28/25 EpiBiologics Presents First Data on c-Met Degrading Bispecific Antibody Read More Jamison Wright 4/28/25 Jamison Wright 4/28/25 Discovery of cMET degrading bispecific antibodies (EpiTACs) for NSCLC and other cMET driven tumors Read More Christine Mackenzie 11/4/24 Christine Mackenzie 11/4/24 EpiBiologics to Present Data Demonstrating Disease-Selective Extracellular Protein Degradation and Platform Breadth at Upcoming Scientific Meetings Read More Christine Mackenzie 4/8/24 Christine Mackenzie 4/8/24 EpiBiologics Extracellular Protein Degraders Demonstrate Robust Preclinical Anti-tumor Activity and Survival Benefit Read More Jamison Wright 4/8/24 Jamison Wright 4/8/24 AACR 2024: EpiBiologics Advances Degraders of Membrane-Bound Proteins Read More Christine Mackenzie 7/20/23 Christine Mackenzie 7/20/23 EpiBiologics Appoints Ann Lee-Karlon as Chief Executive Officer and President, Extends Series A Financing to Over $70 Million Read More Jamison Wright 3/22/23 Jamison Wright 3/22/23 At EpiBiologics, a pair of Genentech alumni wants to make next-gen protein degraders Read More Jamison Wright 3/22/23 Jamison Wright 3/22/23 EpiBiologics Launches with $50 million Series A Financing to Advance Next-Generation Protein Degradation Platform Read More Jamison Wright 9/22/22 Jamison Wright 9/22/22 Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins Read More Jamison Wright 4/28/22 Jamison Wright 4/28/22 Roadmap for Optimizing and Broadening Antibody-Based PROTACs for Degradation of Cell Surface Proteins Read More Jamison Wright 1/4/21 Jamison Wright 1/4/21 Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1 Read More
Jamison Wright 4/28/25 Jamison Wright 4/28/25 EpiBiologics Presents First Data on c-Met Degrading Bispecific Antibody Read More
Jamison Wright 4/28/25 Jamison Wright 4/28/25 Discovery of cMET degrading bispecific antibodies (EpiTACs) for NSCLC and other cMET driven tumors Read More
Christine Mackenzie 11/4/24 Christine Mackenzie 11/4/24 EpiBiologics to Present Data Demonstrating Disease-Selective Extracellular Protein Degradation and Platform Breadth at Upcoming Scientific Meetings Read More
Christine Mackenzie 4/8/24 Christine Mackenzie 4/8/24 EpiBiologics Extracellular Protein Degraders Demonstrate Robust Preclinical Anti-tumor Activity and Survival Benefit Read More
Jamison Wright 4/8/24 Jamison Wright 4/8/24 AACR 2024: EpiBiologics Advances Degraders of Membrane-Bound Proteins Read More
Christine Mackenzie 7/20/23 Christine Mackenzie 7/20/23 EpiBiologics Appoints Ann Lee-Karlon as Chief Executive Officer and President, Extends Series A Financing to Over $70 Million Read More
Jamison Wright 3/22/23 Jamison Wright 3/22/23 At EpiBiologics, a pair of Genentech alumni wants to make next-gen protein degraders Read More
Jamison Wright 3/22/23 Jamison Wright 3/22/23 EpiBiologics Launches with $50 million Series A Financing to Advance Next-Generation Protein Degradation Platform Read More
Jamison Wright 9/22/22 Jamison Wright 9/22/22 Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins Read More
Jamison Wright 4/28/22 Jamison Wright 4/28/22 Roadmap for Optimizing and Broadening Antibody-Based PROTACs for Degradation of Cell Surface Proteins Read More
Jamison Wright 1/4/21 Jamison Wright 1/4/21 Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1 Read More
